Consumer-direct fertility fintech + care platform combining IVF/egg-freezing loans with the US's first nationwide 'Baby or Your Money Back' IVF insurance product. Regulated capital stack — $400M forward-flow lending facility plus a nationwide IVF insurance license/product ('Baby or Your Money Back') — that non-financial fertility competitors cannot easily replicate, combined with 8+ years of fertility loan underwriting data.
Current state: Future Family is scaling after a Sept 2025 CEO transition (healthcare vet Alden Romney in, founder Claire Tomkins moved to Executive Chair) and two major 2025 announcements: the first nationwide IVF insurance 'Baby or Your Money Back' product and a $400M debt/forward-flow financing facility from Clear Haven Capital. Total equity funding stands at ~$45.4M across 5 rounds.
Large, secular-growth market, but heavily contested by employer-benefits incumbents; Future Family's cash-pay + insurance angle serves the ~70% of workers without fertility benefits — a defensible white space.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Future Family | Vertical fertility fintech + care navigation platform: patient-direct IVF/egg-freezing loans and a first-of-its-kind nationwide IVF insurance product ('Baby or Your Money Back'), positioned as the consumer alternative to employer-benefit players. | Series A / SH entry 2020-10-25 | — |
| Progyny (PGNY) | Public employer fertility benefits leader; 650 clinics | Public, ~$2.7B EV Web | FF serves cash-pay/uninsured directly; Progyny only via employer |
| Kindbody | Vertically integrated clinic network + employer benefits | ~$1.8B peak val; has faced markdowns Web | FF is asset-light financing/insurance layer; Kindbody carries clinic capex |
| Carrot Fertility | Flexible reimbursement-model employer benefit | ~$500M val, $114M+ raised Web | FF underwrites patient loans + insurance risk vs. Carrot passing cost to employer |
| Maven Clinic | Broad family/maternity/pediatrics benefits | Unicorn (>$1B) Web | Maven is virtual care benefits marketplace; no direct patient financing |
Moat: Regulated capital stack — $400M forward-flow lending facility plus a nationwide IVF insurance license/product ('Baby or Your Money Back') — that non-financial fertility competitors cannot easily replicate, combined with 8+ years of fertility loan underwriting data.
Base case $500M-$1B strategic sale = 5-10x on entry basis; bull case 10-15x on insurance scale-up
Likely acquirers: Progyny, Carrot Fertility, Maven Clinic, Cigna/Evernorth, UnitedHealth/Optum, Munich Re (existing investor).
Comparable exits: IVI RMA acquired ART Fertility $400-450M (2025) · PureHealth acquired 60% Hellenic Healthcare $2.3B (Jan 2025).